Next Article in Journal
Chronic Kidney Disease and Exposure to Nephrotoxic Metals
Next Article in Special Issue
Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer
Previous Article in Journal
Identifying the Genes Regulated by AtWRKY6 Using Comparative Transcript and Proteomic Analysis under Phosphorus Deficiency
Previous Article in Special Issue
Protease Expression Levels in Prostate Cancer Tissue Can Explain Prostate Cancer-Associated Seminal Biomarkers—An Explorative Concept Study
Open AccessArticle

CTC-mRNA (AR-V7) Analysis from Blood Samples—Impact of Blood Collection Tube and Storage Time

1
Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, 1 Campbell St., Liverpool, NSW 2170, Australia
2
Department of Medical Oncology, Liverpool Hospital, Elizabeth St & Goulburn St, Liverpool, NSW 2170, Australia
3
Western Sydney University Clinical School, Elizabeth St, Liverpool, NSW 2170, Australia
4
South Western Clinical School, University of New South Wales, Goulburn St., Liverpool, NSW 2170, Australia
5
Tokai Pharmaceuticals, Inc., 255 State Street, 6th Floor, Boston, MA 0210, USA
*
Author to whom correspondence should be addressed.
Current address: Siamab Therapeutics, 90 Bridge Street, Suite 100, Newton, MA 02458, USA.
Academic Editor: Carsten Stephan
Int. J. Mol. Sci. 2017, 18(5), 1047; https://doi.org/10.3390/ijms18051047
Received: 31 March 2017 / Revised: 2 May 2017 / Accepted: 8 May 2017 / Published: 12 May 2017
(This article belongs to the Special Issue Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer)
Circulating tumour cells (CTCs) are an emerging resource for monitoring cancer biomarkers. New technologies for CTC isolation and biomarker detection are increasingly sensitive, however, the ideal blood storage conditions to preserve CTC-specific mRNA biomarkers remains undetermined. Here we tested the preservation of tumour cells and CTC-mRNA over time in common anticoagulant ethylene-diamine-tetra-acetic acid (EDTA) and acid citrate dextrose solution B (Citrate) blood tubes compared to preservative-containing blood tubes. Blood samples spiked with prostate cancer cells were processed after 0, 24, 30, and 48 h storage at room temperature. The tumour cell isolation efficiency and the mRNA levels of the prostate cancer biomarkers androgen receptor variant 7 (AR-V7) and total AR, as well as epithelial cell adhesion molecule (EpCAM) were measured. Spiked cells were recovered across all storage tube types and times. Surprisingly, tumour mRNA biomarkers were readily detectable after 48 h storage in EDTA and Citrate tubes, but not in preservative-containing tubes. Notably, AR-V7 expression was detected in prostate cancer patient blood samples after 48 h storage in EDTA tubes at room temperature. This important finding presents opportunities for measuring AR-V7 expression from clinical trial patient samples processed within 48 h—a much more feasible timeframe compared to previous recommendations. View Full-Text
Keywords: circulating tumour cell; biomarker; androgen receptor; AR-V7; droplet digital polymerase chain reaction (ddPCR); blood storage tube circulating tumour cell; biomarker; androgen receptor; AR-V7; droplet digital polymerase chain reaction (ddPCR); blood storage tube
Show Figures

Figure 1

MDPI and ACS Style

Luk, A.W.S.; Ma, Y.; Ding, P.N.; Young, F.P.; Chua, W.; Balakrishnar, B.; Dransfield, D.T.; Souza, P.; Becker, T.M. CTC-mRNA (AR-V7) Analysis from Blood Samples—Impact of Blood Collection Tube and Storage Time. Int. J. Mol. Sci. 2017, 18, 1047.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop